Dihexa Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: preclinical synaptic plasticity mechanisms

Neuro Research peptide-mimetic PowderLyophilizedCapsule verified

Also known as: PNB-0408

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

5 mg, 10 mg, 20 mg, 100 mg, 500 mg

Storage

Use the analytical supplier certificate; no approved human product storage standard exists

Solubility

Formulation-dependent and not accurately described as freely water-soluble; patents and vendors use nonaqueous or specialized vehicles

Catalog Description

Dihexa is an angiotensin-IV-derived peptidomimetic proposed to modulate HGF/c-Met signaling. No completed human clinical trial establishes dosing safety or efficacy. The influential 2014 paper supporting high-affinity HGF binding and synaptogenic mechanism was retracted in April 2025 and must not be cited as valid evidence.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Not established in humans

Onset

Not established in humans; community reports are inconsistent and anecdotal

Administration Routes (Research)

Oral topical and parenteral routes appear in patents or community reports only; no human clinical route is validated

Reported Research Effects

Preclinical neural-plasticity hypotheses
HGF and c-Met mechanism is uncertain after retraction
No demonstrated human cognitive effect

Reported Research Side Effects

Human safety is unknown
Theoretical concern around growth-factor and c-Met signaling
Gray-market identity and purity risk

Data source: Retraction notice, remaining preclinical literature, registry search, and current market checks

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

No human dosing protocol has been established [Not established; Not established; Not established]Source: no completed human clinical trial and foundational paper retracted

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Other unvalidated growth-factor agonists
Active or suspected malignancy as a theoretical c-Met concern

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

Human decision required: remove all former dosing claims and add the 2025 retraction prominently. Current gray-market products range from 5-20 mg vials or capsules to 100-500 mg powder. Reddit reports confirm the larger powder market but also document sourcing and quality concerns.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Retracted procognitive and synaptogenic Dihexa paper — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/25187433/

Retraction notice PMID 40312093 — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/40312093/

Preclinical lateral-line hair-cell study — PubMed Central (NIH)
https://pmc.ncbi.nlm.nih.gov/articles/PMC4309183/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.